logo-loader
RNS
view4D pharma plc

4d Pharma PLC - Director/PDMR Shareholding

RNS Number : 5885G
4d Pharma PLC
18 March 2020
 

 

 The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

4D pharma plc

(the "Company" or "4D")

PDMR Dealings

4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics, is pleased to announce that David Norwood (the "Director") has purchased ordinary shares in the Company as listed below. Following this transaction, the Director has a resulting interest in the ordinary shares of the Company as listed below.

Name


Shares in 4D pharma plc before purchase

% of total shares in issue

Shares in 4D pharma plc after purchase

% of total shares in issue







David Norwood (Chairman)


8,457,061

7.7%

 8,557,061

7.8%

 

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

David Norwood

2

Reason for the notification

a)

Position/status

Chairman/ PDMR

b)

 

Initial notification /Amendment

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

4D Pharma plc

b)

LEI

213800O49VYSXWE2ZD52

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Identification code

Ordinary shares of £0.0025

 

ISIN: GB00BJL5BR07

b)

Nature of the transaction

Purchase of Ordinary Shares

c)

Price(s) and volume(s)

 Price(s)

Volume(s)

28p

100,000

d)

Aggregated information

- Aggregated volume

- Price

 

N/A

 

e)

Date of the transaction

17th March 2020

f)

Place of the transaction

London Stock Exchange, AIM

 






 

For further information please contact:

4D


Duncan Peyton, Chief Executive Officer

[email protected]

+ 44 (0)113 895 0130

 

 

N+1 Singer - Nominated Adviser and Joint Broker

+44 (0) 20 7496 3000

Aubrey Powell / Justin McKeegan / Alex Bond (Corporate Finance)

Tom Salvesen (Corporate Broking)

 


Bryan Garnier & Co. Limited - Joint Broker

+44 (0)20 7332 2500

Dominic Wilson / Phil Walker




 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
DSHEAXDPFLKEEEA

Quick facts: 4D pharma plc

Price: 53

Market: AIM
Market Cap: £58.03 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE